BDSX BIODESIX INC

Nasdaq biodesix.com


$ 7.46 $ 0.00 (0 %)    

Wednesday, 15-Oct-2025 04:00:07 EDT
QQQ $ 603.37 $ 0.00 (0 %)
DIA $ 464.68 $ 0.00 (0 %)
SPY $ 666.39 $ 0.00 (0 %)
TLT $ 90.99 $ 0.00 (0 %)
GLD $ 387.04 $ 0.00 (0 %)
$ 7.79
$ 7.37
$ 7.46 x 56
$ 7.97 x 100
-- - --
$ 3.44 - $ 34.40
31,065
na
57.11M
$ 0.48
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-03-2025 01-01-1970 10-K
4 11-01-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-01-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-06-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-14-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-16-2021 12-31-2020 10-K
20 12-10-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 canaccord-genuity-maintains-buy-on-biodesix-lowers-price-target-to-20

Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and lowers the price target from $30 to $20.

 stock-market-today-dow-futures-slip-nasdaq-rises-as-trump-files-tariff-appealamerican-eagle-salesforce-lululemon-in-focus-updated

U.S. stock futures were swinging on Thursday following Wednesday's mixed moves. Futures of major benchmark indices were mixed.

 biodesix-stock-surges-over-51-overnight-after-jack-schulers-15m-share-purchase-revealed

Biodesix shares surged over 51% in after-hours trading after major shareholder Jack W. Schuler disclosed a $1.5 million insider...

 biodesix-sees-fy2025-sales-80000m-85000m-vs-82013m-est

Biodesix (NASDAQ:BDSX) sees FY2025 sales of $80.000 million-$85.000 million vs $82.013 million analyst estimate.

 biodesix-q2-eps-008-misses-007-estimate-sales-20018m-beat-18463m-estimate

Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by...

 biodesix-has-been-granted-european-patent-number-ep3698144-titled-compositions-methods-and-kits-for-diagnosis-of-lung-cancer

https://register.epo.org/application?number=EP18868355

 biodesix-to-present-new-insight-study-data-at-asco-2025-showing-veristrat-test-predicts-improved-survival-with-chemoimmunotherapy-over-immunotherapy-alone-in-pd-l1-50-metastatic-nsclc-patients-with-poor-immune-classifier

Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 20...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION